Phase 1, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XEN901 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 20 Mar 2018
At a glance
- Drugs XEN 901 (Primary)
- Indications Epilepsy
- Focus Adverse reactions
- Sponsors Xenon Pharmaceuticals
- 20 Feb 2018 According to a Xenon Pharmaceuticals media release, the Clinical Trial Application (CTA) for XEN901 has been excepted by Medicines & Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK).
- 20 Feb 2018 According to a Xenon Pharmaceuticals media release, the first patient has been dosed in this study. Results are anticipated in the second half of 2018.
- 20 Feb 2018 Status changed from planning to recruiting, according to a Xenon Pharmaceuticals media release .